论文部分内容阅读
目的观察(R)-EPOCH方案治疗MYC和BCL-2阳性弥漫大B细胞淋巴瘤(DLBCL)的近期疗效及不良反应。方法选择病理确诊的MYC和BCL-2阳性DLBCL患者28例,应用(R)-EPOCH方案化疗,观察其近期疗效和不良反应。具体用药为依托泊苷每天50 mg/m~2,多柔比星(ADM)或吡柔比星(THP)每天10 mg/m~2,长春新碱(VCR)每天0.4 mg/m~2持续静脉滴注,第1~4天,环磷酰胺(CTX)每天750 mg/m~2静脉滴注第5天,泼尼松每天60 mg/m~2口服第1~5天,21 d为一疗程。结果患者接受4个周期的(R)-EPOCH方案治疗后评价疗效,CR率为64.3%(18/28),PR率为25.0%(7/28),总有效率为89.3%,主要不良反应为骨髓抑制。结论 (R)-EPOCH方案可作为MYC和BCL-2阳性弥漫大B细胞淋巴瘤的初始治疗方案,缓解率高,不良反应可耐受,其长期疗效有待进一步观察。
Objective To observe the short-term efficacy and side effects of (R) -EPOCH regimen in the treatment of MYC and BCL-2 positive diffuse large B cell lymphoma (DLBCL). Methods 28 patients with pathologically confirmed MYC and BCL-2 positive DLBCL were treated with (R) -EPOCH regimen and observed their short-term efficacy and adverse reactions. Specific use of etoposide daily 50 mg / m ~ 2, doxorubicin (ADM) or pirarubicin (THP) daily 10 mg / m ~ 2, vincristine (VCR) daily 0.4 mg / m ~ 2 Continuous intravenous drip, the first 4 days, cyclophosphamide (CTX) daily 750 mg / m ~ 2 intravenous drip on the 5th day, prednisone 60 mg / m ~ 2 oral day 1 to 5, 21 d For a course of treatment. Results The patients were evaluated by 4 cycles of (R) -EPOCH regimen. The CR rate was 64.3% (18/28), the PR rate was 25.0% (7/28) and the total effective rate was 89.3%. The major adverse reactions For myelosuppression. Conclusion The (R) -EPOCH regimen can be used as initial treatment for MYC and BCL-2 positive diffuse large B cell lymphoma with high remission rate and tolerable side effects. The long-term therapeutic effect needs to be further observed.